Invivyd (NASDAQ:IVVD) Insider Timothy Edward Lee Sells 20,013 Shares

Key Points

• Insider Timothy Edward Lee sold 20,013 shares of Invivyd stock on August 18th at an average price of $0.65, resulting in an 18.36% decrease in his ownership.
• Invivyd reported a quarterly earnings loss of ($0.12) per share, missing analysts' estimates, with revenue of $11.79 million compared to expected $23.16 million.
• The stock's market cap is approximately $68.60 million, with current trading at around $0.5710 and a 1-year performance range between $0.3546 and $2.74.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Timothy Edward Lee sold 20,013 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $0.65, for a total transaction of $13,008.45. Following the sale, the insider directly owned 88,987 shares in the company, valued at approximately $57,841.55. The trade was a 18.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Timothy Edward Lee also recently made the following trade(s):

• On Tuesday, August 19th, Timothy Edward Lee sold 29,643 shares of Invivyd stock. The stock was sold at an average price of $0.57, for a total transaction of $16,896.51.

Invivyd Stock Performance

IVVD stock traded down $0.0101 during midday trading on Tuesday, reaching $0.5710. 1,690,635 shares of the company were exchanged, compared to its average volume of 850,421. Invivyd, Inc. has a 1-year low of $0.3546 and a 1-year high of $2.74. The stock's 50-day simple moving average is $0.75 and its 200 day simple moving average is $0.84. The company has a market cap of $68.60 million, a price-to-earnings ratio of -0.62 and a beta of 0.51.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). The company had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%. On average, research analysts anticipate that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IVVD shares. HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Invivyd in a report on Thursday, June 26th. D. Boral Capital decreased their price objective on Invivyd from $9.00 to $3.00 and set a "buy" rating for the company in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to data from MarketBeat.com, Invivyd presently has a consensus rating of "Buy" and an average target price of $3.85.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. 683 Capital Management LLC increased its holdings in shares of Invivyd by 2.3% in the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company's stock valued at $2,195,000 after purchasing an additional 70,000 shares during the period. Jane Street Group LLC acquired a new stake in shares of Invivyd in the 2nd quarter valued at approximately $147,000. Marshall Wace LLP acquired a new stake in shares of Invivyd in the 2nd quarter valued at approximately $158,000. Invesco Ltd. lifted its holdings in shares of Invivyd by 25.5% in the 2nd quarter. Invesco Ltd. now owns 136,755 shares of the company's stock valued at $98,000 after buying an additional 27,756 shares during the period. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of Invivyd in the 2nd quarter valued at approximately $27,000. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.